Live chat

Associate Scientist II, Bioassay

Biogen - Cambridge, MA

•\tDevelop and automate purified and cell-free assays in a variety of formats, including FRET, TR-FRET, MSD, luminescence, FP, RF-MS, and ELISA

•\tDesign, execute, and troubleshoot experiments with minimal supervision; analyze and interpret results

•\tPerform data analysis and visualization using appropriate software

•\tEffectively communicate verbally and in writing, prepare and deliver concise and clear presentations at project team and group meetings

•\tCollaborate with colleagues to run high-throughput screens and to analyze HTS data

•\tEfficiently manage time to enable pursuit of multiple objectives in parallel

Requisition Number


Employment Category

Full-Time Regular

External Posting Title

Associate Scientist II / III, Bioassays and High-Throughput Screens

Job Category

Research & Development


Industrial experience in small-molecule testing and assay development is preferred. Familiarity with high-density assay plate formats and automated liquid handling devices is essential, such as instruments made by Tecan, Labcyte, Hamilton, BioTek, TTP Labtech, and Thermo Scientific. Experience performing assay data analysis using software such as Genedata Screener, Spotfire, and Prism. Experience with mammalian cell culture and assay systems is a plus. Must be a team player who is willing to work effectively in small teams to accomplish key deliverables. Demonstrated ability to successfully take on new challenges, quickly adapt to changing priorities, communicate effectively, and efficiently manage time to pursue multiple objectives in parallel. Must be able to thrive in a fast-paced, dynamic work environment.


B.S. or M.S. degree in biochemistry, cell biology, or a related discipline.

Experience Level



Biogen is looking for a highly motivated and collaborative scientist to join the Bioassays and High-Throughput Screens group in the Biotherapeutics and Medicinal Sciences department. This successful candidate will develop, optimize, implement, and trouble-shoot innovative cell-based and purified-component assays and screens in high-density plate formats using cutting-edge automation and assay technologies. The primary focus of this role is to provide enabling in vitro assay support to accelera


11 days 2 hours ago



Associate Scientist II, Bioassay Biogen - Cambridge, MA, United States


Location: Cambridge, MA

Company Profile:
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin’s lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company’s products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company’s Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.